Over the past decade, big data and artificial intelligence (AI) have become standard concepts in digestive disease research, both as individual tools and applied together…
State of the art - omic methods now provide deeper insight into the biologic architecture of IBD. This session will review state of the art advances in metabolomics, transcriptomics, and epigenetics in defining the biologic basis of IBD…
Aconitate decarboxylase 1 (ACOD1; also known as IRG-1) is the ubiquitous source of the metabolite itaconate, which dampens inflammasome activation by preventing HIF1α production of IL-1β and prevents TNF production through NRF2 activation…
The risk of bowel surgery in patients with Inflammatory Bowel Disease (IBD) and Clostridioides difficile infection (CDI) can change rapidly over the course of the disease…
Introduction: The molecular mechanism by which effector CD4+ T helper (Th) cells remain activated to possibly mediate resistance to biologics and consequent refractory human inflammatory bowel disease (IBD) is not clear…
BACKGROUND: Darvadstrocel (DVS), a suspension of expanded allogeneic adipose-derived mesenchymal stem cells, is approved for the treatment of complex Crohn’s perianal fistulas (CPF)…
BACKGROUND: Immune activation by immune checkpoint inhibitors (ICI) has shown promise in the treatment of diverse cancer types at the cost of different immune-related adverse events (irAEs)…
BACKGROUND: Tofacitinib and upadacitinib are JAK inhibitors (JAKi) approved for Inflammatory Bowel Disease (IBD) treatment. Response rates to JAKi in IBD are varied, and there are concerns for serious side effects like venous thromboembolism, cancer and cardiovascular events…
BACKGROUND: The pathogenesis of Inflammatory Bowel Disease (IBD) is a multifactorial process characterized by inflammation and damage to the intestinal barrier, which is made up of intestinal epithelial cells (IECs)…